Evidence map›Paper›PMID 32734735›Full record

ArticleYonsei medical journal2020

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator.

Hyeok Chan Kwon, Minyoung Kevin Kim, Jason Jungsik Song, Yong Beom Park, Sang Won Lee

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Yonsei medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05716334 (Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05716334 completednot on this mapstarted 2021, after this paper: background citation

Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): a CanVasc Multicentre Study

TypeobservationalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2021 to 2025Enrolled201ConditionsANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Updates in ANCA-associated vasculitis.European journal of rheumatology · 2022
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hyeok Chan KwonDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0641-5613
Minyoung Kevin KimDepartment of Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-4826-3232
Jason Jungsik SongDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0662-7704
Yong Beom ParkDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-4695-8620
Sang Won LeeDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8038-3341
Yonsei University · KR

Funding

Korea Health Industry Development Institute HI14C1324
6 · The paper itself

Abstract

purposeThere has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and GPA in Korean patients, and compared those between Mabthera® and Truxima®. MATERIALS AND

methodsWe retrospectively reviewed the medical records of a total of 139 patients, including 97 MPA patients and 42 GPA patients. At diagnosis, antineutrophil cytoplasmic antibody positivity and comorbidities were assessed. During follow-up, all-cause mortality, relapse, end-stage renal disease, cerebrovascular accident and acute coronary syndrome were evaluated as poor outcomes. In this study, rituximab was used as either Mabthera® or Truxima®.

resultsThe median age at diagnosis was 60.1 years and 46 patients were men (97 MPA and 42 GPA patients). Among poor outcomes, patients receiving rituximab exhibited a significantly lower cumulative relapse-free survival rate compared to those not receiving rituximab (

conclusionTruxima® prevents poor outcomes of MPA and GPA as effectively as does Mabthera®.

Indexed as

Biosimilar PharmaceuticalsFemaleGranulomatosis with PolyangiitisHumansMaleMicroscopic PolyangiitisMiddle AgedPrognosisRecurrenceRetrospective StudiesRituximabSurvival RateTreatment OutcomeBiosimilar PharmaceuticalsRituximabbiosimilargranulomatosis with polyangiitismicroscopic polyangiitisprognosisRituximab

Identifiers

PMID32734735
PMCPMC7393299
OpenAlexW3045688026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.